Improving Medication Safety and CVD Risk Factor Control in Kidney Transplant Recipients

NCT02763943 | Completed

• 1 other identifier: Pro00051804
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

There is a lack of data analyzing the influence of Cardio-vascular Diseases (CVD) risk factor control on graft survival disparities in Black transplant recipients. Studies in the general population indicate that CVD risk factor control is poor in Black patients, leading to higher rates of renal failure and CV events. However, with the exception of hypertension, there is paucity in data demonstrating similar results within transplant recipients. Recent analyses conducted within our transplant program, indicate that CVD risk factors, especially diabetes, are poorly controlled in Black recipients, which likely impacts graft loss. Since these data were collected in a retrospective manner, larger analyses are needed to validate these exploratory findings. This pilot study is to:

1. 1.Determine if the study is feasible, as measured by the proportions of enrolled to approached and completed to enrolled.
2. 2.Measure and compare, at baseline versus the end of the intervention, the medication safety events, including the number of medication errors, medication non-adherence and medication side effects, in patients enrolled in the study
3. 3.Measure and compare, at baseline versus the end of the intervention, CVD risk factor control, including hypertension, diabetes and dyslipidemia, in patients enrolled in the study
4. 4.Measure and compare, at baseline versus the end of the intervention, patient reported survey results, in patients enrolled in the study
5. 5.Determine if the impact of the intervention is more pronounced in Black recipients, as compared to non-Black recipients

Conditions

Cardiovascular Diseases; Diabetes Mellitus; Medication Adherence

Outcome Measures

Primary Outcomes (9)

• Change in blood pressure values from baseline to end of study

  Blood pressure will be assessed using clinic measurements, taken three times, five minutes apart in the same arm and averaged.

  6 months

• Change in HBA1C values from baseline to end of study

  6 months

• Change in lipid values from baseline to end of study

  6 months

• Medication adherence by comparing medication possession ratios (MPR) for the six months prior to enrollment compared to six months during the intervention

  1 year

• Patient self-reported medication adherence at baseline compared to end of study.

  The Morisky 8-item adherence score will be compared from baseline to end of study.

  6 months

• Number of medication errors assessed at baseline and compared to errors at 6 months

  6 months

• Medication side effects at baseline compared to end of study.

  The Memphis side effect scale will be used to compare side effects from baseline to end of study.

  6 months

• Patient reported survey results regarding self-care and health knowledge from baseline to end of study

  6 months

• Patient reported survey results regarding psychosocial status from baseline to end of study

  6 months

Interventions

Pharmacist-led, technology enabled education intervention BEHAVIORAL

Prospective, non-randomized, pilot study assessing the feasibility and potential efficacy of a 6-month, pharmacist-led, technology enabled education intervention on improving medication safety and cardiovascular risk factor control in adult solitary kidney transplant recipients with a secondary aim of assessing if the impact of the intervention varies by race.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• At least 18 years of age and able to give informed consent.
• Received a first or repeat cadaveric or living donor renal transplant.
• Patient has adequate graft function, defined as an estimated glomerular filtration rate (GFR) of at least 20 mL/min, using the 4-variable Modification of Diet in Renal Disease (MDRD) equation.
• Patient is at least one year post transplant.
• Patient has documented hypertension, defined as a sitting blood pressure of at least 140/90 mmHg or receiving any anti-hypertensive therapy.
• Patient has documented diabetes mellitus, defined as a hemoglobin A1c of at least 6.5% or receiving any anti-glycemic medications.
• Willing to comply with all study visits.

You may not qualify if:

• Biopsy proven acute rejection episode that occurred within the past month.
• Patients who have received an organ transplant other than a kidney.

Sponsors & Collaborators

• Medical University of South Carolina: lead
• National Institutes of Health (NIH): collaborator

Study Sites (1)

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

Related Publications (1)

• Taber DJ, Gebregziabher M, Posadas A, Schaffner C, Egede LE, Baliga PK. Pharmacist-Led, Technology-Assisted Study to Improve Medication Safety, Cardiovascular Risk Factor Control, and Racial Disparities in Kidney Transplant Recipients. J Am Coll Clin Pharm. 2018 Dec;1(2):81-88. doi: 10.1002/jac5.1024. Epub 2018 Jun 21.

  PMID: 30714026 DERIVED

MeSH Terms

Conditions

Cardiovascular Diseases; Diabetes Mellitus; Medication Adherence

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Patient Compliance; Patient Acceptance of Health Care; Treatment Adherence and Compliance; Health Behavior; Behavior

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 14, 2016
• First Posted: May 5, 2016
• Study Start: April 1, 2016
• Primary Completion: January 22, 2018
• Study Completion: January 22, 2018
• Last Updated: February 12, 2018

Record last verified: 2016-04

Locations

US (1)